Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Ultragenyx Pharmaceu (RARE)

Ultragenyx Pharmaceu (RARE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,531,541
  • Shares Outstanding, K 57,771
  • Annual Sales, $ 51,500 K
  • Annual Income, $ -197,610 K
  • 60-Month Beta 2.35
  • Price/Sales 35.04
  • Price/Cash Flow N/A
  • Price/Book 4.99

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/20
See More
  • Average Estimate -1.63
  • Number of Estimates 3
  • High Estimate -1.44
  • Low Estimate -1.94
  • Prior Year -1.82
  • Growth Rate Est. (year over year) +10.44%

Price Performance

See More
Period Period Low Period High Performance
1-Month
51.02 +19.82%
on 01/31/20
64.24 -4.84%
on 02/14/20
-0.23 (-0.37%)
since 01/14/20
3-Month
35.41 +72.63%
on 11/18/19
64.24 -4.84%
on 02/14/20
+24.35 (+66.20%)
since 11/14/19
52-Week
35.41 +72.63%
on 11/18/19
74.50 -17.95%
on 04/05/19
+5.67 (+10.22%)
since 02/14/19

Most Recent Stories

More News
Ultragenyx (RARE) Reports Wider-Than-Expected Loss in Q4

Ultragenyx (RARE) reports a wider-than-expected loss and beats sales estimates in the fourth quarter of 2019.

BAYRY : 21.0200 (+0.24%)
RARE : 61.13 (-2.81%)
AVXL : 5.00 (+0.60%)
GH : 84.30 (+3.06%)
Ultragenyx: 4Q Earnings Snapshot

NOVATO, Calif. (AP) _ Ultragenyx Pharmaceutical Inc. (RARE) on Thursday reported a loss of $93.8 million in its fourth quarter.

RARE : 61.13 (-2.81%)
Ultragenyx Reports Fourth Quarter and Full Year 2019 Financial Results and Corporate Update

2019 total revenue is $103.7 million; 2019 Crysvita (burosumab) revenue to Ultragenyx is $87.3 million

RARE : 61.13 (-2.81%)
Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2019 Financial Results and Corporate Update

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, today announced that it will host...

RARE : 61.13 (-2.81%)
Ultragenyx Pharm Has Returned 36.5% Since SmarTrend Recommendation (RARE)

SmarTrend identified an Uptrend for Ultragenyx Pharm (NASDAQ:RARE) on December 3rd, 2019 at $40.80. In approximately 2 months, Ultragenyx Pharm has returned 36.52% as of today's recent price of $55.70....

RARE : 61.13 (-2.81%)
Ultragenyx Pharm Up 47.0% Since SmarTrend Uptrend Call (RARE)

SmarTrend identified an Uptrend for Ultragenyx Pharm (NASDAQ:RARE) on December 3rd, 2019 at $40.80. In approximately 2 months, Ultragenyx Pharm has returned 46.96% as of today's recent price of $59.96....

RARE : 61.13 (-2.81%)
GeneTx and Ultragenyx Announce Investigational New Drug (IND) Application Active for GTX-102 in Patients with Angelman Syndrome

GeneTx Biotherapeutics LLC and Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare diseases, today announced...

RARE : 61.13 (-2.81%)
Thinking about buying stock in Bank of America, Nio, Ultragenyx Pharmaceutical, Tilray, or Walmart?

InvestorsObserver issues critical PriceWatch Alerts for BAC, NIO, RARE, TLRY, and WMT.

BAC : 34.85 (-0.17%)
NIO : 3.77 (-6.45%)
RARE : 61.13 (-2.81%)
TLRY : 17.39 (+7.81%)
WMT : 117.89 (+0.38%)
Ultragenyx Provides Preliminary Crysvita 2019 Revenues

Ultragenyx (RARE) provides preliminary 2019 revenue numbers and 2020 outlook for Crysvita, along with other pipeline updates.

RARE : 61.13 (-2.81%)
CLSN : 1.35 (+0.41%)
ALXN : 102.56 (-0.83%)
ASLN : 2.11 (-1.73%)
34.5% Return Seen to Date on SmarTrend Ultragenyx Pharm Call (RARE)

SmarTrend identified an Uptrend for Ultragenyx Pharm (NASDAQ:RARE) on December 3rd, 2019 at $40.80. In approximately 1 month, Ultragenyx Pharm has returned 34.51% as of today's recent price of $54.88....

RARE : 61.13 (-2.81%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Weakening short term outlook on maintaining the current direction.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Trade RARE with:

Business Summary

Ultragenyx Pharmaceutical Inc. is involved in the identification, acquisition, development and commercialization of products for the treatment of rare and ultra-rare diseases, with an initial focus on serious, debilitating metabolic genetic diseases. The Company's product pipeline include KRN23 (UX023)...

See More

Key Turning Points

2nd Resistance Point 65.76
1st Resistance Point 63.45
Last Price 61.13
1st Support Level 59.61
2nd Support Level 58.08

See More

52-Week High 74.50
Last Price 61.13
Fibonacci 61.8% 59.57
Fibonacci 50% 54.96
Fibonacci 38.2% 50.34
52-Week Low 35.41

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar